| Ytd | ||
| 1y |
| Open | 46.99 | Prev Close | 46.99 | Low | 46.99 | High | 46.99 | Mkt Cap | 3.54B |
| Vol | 5.01M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -21.96 |
| Beta | 0.70 | Short Ratio | 1.46 | Inst. Own | 87.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 47.00 |
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size redu
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size re
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 toplin
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technolog
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the E
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks C
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Sp
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the comp
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Frid
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceut
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Tuesday, 596 companies set new 52-week highs.
Monday morning saw 558 companies set new 52-week highs.
Before 10 a.m. ET on Thursday, 166 companies hit new 52-week highs.
During Tuesday's morning session, 342 companies made new 52-week highs.
During Thursday's morning session, 316 companies made new 52-week highs.
This morning 167 companies reached new 52-week highs.
Before 10 a.m. ET on Wednesday, 322 companies hit new 52-week highs.
Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs.
This morning 180 companies set new 52-week highs.
Friday's morning session saw 144 companies set new 52-week highs.
85 Biggest Movers From Yesterday
71 Biggest Movers From Yesterday
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday